tradingkey.logo

Aldeyra Receives Complete Response Letter From The FDA For The Reproxalap New Drug Application For The Treatment Of Dry Eye Disease

ReutersApr 3, 2025 12:13 PM

- Aldeyra Therapeutics Inc ALDX.O:

  • ALDEYRA THERAPEUTICS RECEIVES COMPLETE RESPONSE LETTER FROM THE U.S. FOOD AND DRUG ADMINISTRATION FOR THE REPROXALAP NEW DRUG APPLICATION FOR THE TREATMENT OF SIGNS AND SYMPTOMS OF DRY EYE DISEASE

  • ALDEYRA THERAPEUTICS INC -NEW DRUG APPLICATION RESUBMISSION EXPECTED MID-YEAR 2025

  • ALDEYRA THERAPEUTICS INC -TOP-LINE DATA FROM DRY EYE CHAMBER TRIAL AND FIELD TRIAL EXPECTED IN Q2 2025

  • ALDEYRA THERAPEUTICS - LETTER IDENTIFIED CONCERNS WITH DATA FROM TRIAL SUBMITTED TO NDA THAT MAY HAVE AFFECTED INTERPRETATION OF RESULTS

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI